Skip to main content
Top
Published in: Health and Quality of Life Outcomes 1/2005

Open Access 01-12-2005 | Research

The two-year impact of first generation protease inhibitor based antiretroviral therapy (PI-ART) on health-related quality of life

Authors: Lars E Eriksson, Göran A Bratt, Eric Sandström, Gun Nordström

Published in: Health and Quality of Life Outcomes | Issue 1/2005

Login to get access

Abstract

Background

Protease inhibitor based antiretroviral therapy (PI-ART) was introduced in 1996 and has greatly reduced the incidence of HIV-related morbidity and mortality in the industrialised world. PI-ART would thus be expected to have a positive effect on health-related quality of life (HRQL). On the other hand, HRQL might be negatively affected by strict adherence requirements as well as by short and long-term adverse effects. The aim of this study was to assess the influence of two years of first generation PI-ART on HRQL in patients with a relatively advanced state of HIV-infection. Furthermore, we wanted to investigate the relation between developments in HRQL and viral response, self-reported adherence and subjective experience of adverse effects in patients with PI-ART.

Methods

HRQL was measured by the Swedish Health-Related Quality of Life Questionnaire (SWED-QUAL). Sixty-three items from the SWED-QUAL forms two single-item and 11 multi-item dimension scales. For this study, two summary SWED-QUAL scores (physical HRQL composite score and emotional HRQL composite score) were created through a data reduction procedure. At the 2-year follow-up measurement (see below), items were added to measure adherence and subjective experience of adverse effects. Demographic and medical data were obtained from specific items in the questionnaires and from the medical files. Seventy-two patients who were among the first to receive PI-ART (indinavir or ritonavir based) responded to the questionnaire before the start of PI-ART. Of these, 54 responded to the same instrument after two years of treatment (13 had died, four had changed clinic and one did not receive the questionnaire).

Results

The main findings were that the emotional HRQL deteriorated during two years of PI-ART, while the physical HRQL remained stable. Multiple linear regression analyses showed that experience of adverse effects contributed most to the deterioration of emotional HRQL.

Conclusion

In this sample of patients with relatively advanced state of HIV-infection, our data suggested that a negative development of physical HRQL had been interrupted by the treatment and that the emotional dimension of HRQL deteriorated during two years after start of PI-ART. Subjective experience of adverse effects made a major contribution to the decrease in emotional HRQL. The results underline the importance of including HRQL measures in the evaluation of new life prolonging therapies.
Literature
1.
go back to reference British HIV Association Writing Committee: British HIV Association (BHIVA) guidelines for the treatment of HIV-infected adults with antiretroviral therapy. HIV Med 2003,4(Suppl 1):1–41. British HIV Association Writing Committee: British HIV Association (BHIVA) guidelines for the treatment of HIV-infected adults with antiretroviral therapy. HIV Med 2003,4(Suppl 1):1–41.
2.
go back to reference Palella FJ Jr, Delaney KM, Moorman AC, Loveless MO, Fuhrer J, Satten GA, Aschman DJ, Holmberg SD: Declining morbidity and mortality among patients with advanced human immunodeficiency virus infection. HIV Outpatient Study Investigators. N Engl J Med 1998, 338: 853–860. 10.1056/NEJM199803263381301PubMedCrossRef Palella FJ Jr, Delaney KM, Moorman AC, Loveless MO, Fuhrer J, Satten GA, Aschman DJ, Holmberg SD: Declining morbidity and mortality among patients with advanced human immunodeficiency virus infection. HIV Outpatient Study Investigators. N Engl J Med 1998, 338: 853–860. 10.1056/NEJM199803263381301PubMedCrossRef
3.
go back to reference Mocroft A, Katlama C, Johnson AM, Pradier C, Antunes F, Mulcahy F, Chiesi A, Phillips AN, Kirk O, Lundgren JD: AIDS across Europe, 1994–98: the EuroSIDA study. Lancet 2000, 356: 291–296. 10.1016/S0140-6736(00)02504-6PubMedCrossRef Mocroft A, Katlama C, Johnson AM, Pradier C, Antunes F, Mulcahy F, Chiesi A, Phillips AN, Kirk O, Lundgren JD: AIDS across Europe, 1994–98: the EuroSIDA study. Lancet 2000, 356: 291–296. 10.1016/S0140-6736(00)02504-6PubMedCrossRef
4.
go back to reference Safrin S, Grunfeld C: Fat distribution and metabolic changes in patients with HIV infection. AIDS 1999, 13: 2493–2505. 10.1097/00002030-199912240-00002PubMedCrossRef Safrin S, Grunfeld C: Fat distribution and metabolic changes in patients with HIV infection. AIDS 1999, 13: 2493–2505. 10.1097/00002030-199912240-00002PubMedCrossRef
5.
go back to reference Carr A, Cooper DA: Adverse effects of antiretroviral therapy. Lancet 2000, 356: 1423–1430. 10.1016/S0140-6736(00)02854-3PubMedCrossRef Carr A, Cooper DA: Adverse effects of antiretroviral therapy. Lancet 2000, 356: 1423–1430. 10.1016/S0140-6736(00)02854-3PubMedCrossRef
6.
go back to reference Ragsdale D, Morrow JR: Quality of life as a function of HIV classification. Nurs Res 1990, 39: 355–359.PubMedCrossRef Ragsdale D, Morrow JR: Quality of life as a function of HIV classification. Nurs Res 1990, 39: 355–359.PubMedCrossRef
7.
go back to reference Wu AW, Rubin HR, Mathews WC, Ware JE, Brysk LT, Hardy WD, Bozzette SA, Spector SA, Richman DD: A health status questionnaire using 30 items from the Medical Outcomes Study. Med Care 1991, 29: 786–798.PubMedCrossRef Wu AW, Rubin HR, Mathews WC, Ware JE, Brysk LT, Hardy WD, Bozzette SA, Spector SA, Richman DD: A health status questionnaire using 30 items from the Medical Outcomes Study. Med Care 1991, 29: 786–798.PubMedCrossRef
8.
go back to reference Wachtel T, Piette J, Mor V, Stein M, Fleishman J, Carpenter C: Quality of life in persons with human immunodeficiency virus infection: Measurement by the Medical Outcomes Study Instrument. Ann Intern Med 1992, 116: 129–137.PubMedCrossRef Wachtel T, Piette J, Mor V, Stein M, Fleishman J, Carpenter C: Quality of life in persons with human immunodeficiency virus infection: Measurement by the Medical Outcomes Study Instrument. Ann Intern Med 1992, 116: 129–137.PubMedCrossRef
9.
go back to reference Holzemer WL, Wilson HS: Quality of life and the spectrum of HIV infection. Annu Rev Nurs Res 1995, 13: 3–29.PubMed Holzemer WL, Wilson HS: Quality of life and the spectrum of HIV infection. Annu Rev Nurs Res 1995, 13: 3–29.PubMed
10.
go back to reference Wu AW, Rubin HR: Approaches to health status assessment in HIV disease overview of the conference. Psychol Health 1994, 9: 1–18.CrossRef Wu AW, Rubin HR: Approaches to health status assessment in HIV disease overview of the conference. Psychol Health 1994, 9: 1–18.CrossRef
11.
go back to reference Call SA, Klapow JC, Stewart KE, Westfall AO, Mallinger AP, DeMasi RA, Centor R, Saag MS: Health-related quality of life and virologic outcomes in an HIV clinic. Qual Life Res 2000, 9: 977–985. 10.1023/A:1016668802328PubMedCrossRef Call SA, Klapow JC, Stewart KE, Westfall AO, Mallinger AP, DeMasi RA, Centor R, Saag MS: Health-related quality of life and virologic outcomes in an HIV clinic. Qual Life Res 2000, 9: 977–985. 10.1023/A:1016668802328PubMedCrossRef
12.
go back to reference Lorenz KA, Shapiro MF, Asch SM, Bozzette SA, Hays RD: Associations of symptoms and health-related quality of life: findings from a national study of persons with HIV infection. Ann Intern Med 2001, 134: 854–860.PubMedCrossRef Lorenz KA, Shapiro MF, Asch SM, Bozzette SA, Hays RD: Associations of symptoms and health-related quality of life: findings from a national study of persons with HIV infection. Ann Intern Med 2001, 134: 854–860.PubMedCrossRef
13.
go back to reference Murri R, Fantoni M, Borgo CD, Visona R, Barracco A, Zambelli A, Testa L, Orchi N, Tozzi V, Bosco O, Wu AW: Determinants of health-related quality of life in HIV-infected patients. AIDS Care 2003, 15: 581–590. 10.1080/0954012031000134818PubMedCrossRef Murri R, Fantoni M, Borgo CD, Visona R, Barracco A, Zambelli A, Testa L, Orchi N, Tozzi V, Bosco O, Wu AW: Determinants of health-related quality of life in HIV-infected patients. AIDS Care 2003, 15: 581–590. 10.1080/0954012031000134818PubMedCrossRef
14.
go back to reference Ichikawa M, Natpratan C: Quality of life among people living with HIV/AIDS in northern Thailand: MOS-HIV Health Survey. Qual Life Res 2004, 13: 601–610. 10.1023/B:QURE.0000021319.73865.5aPubMedCrossRef Ichikawa M, Natpratan C: Quality of life among people living with HIV/AIDS in northern Thailand: MOS-HIV Health Survey. Qual Life Res 2004, 13: 601–610. 10.1023/B:QURE.0000021319.73865.5aPubMedCrossRef
15.
go back to reference Kemmler G, Schmied B, Shetty-Lee A, Zangerle R, Hinterhuber H, Schüssler G, Mumelter B: Quality of life of HIV-infected patients: psychometric properties and validation of the German version of the MQOL-HIV. Qual Life Res 2003, 12: 1037–1050. 10.1023/A:1026114004548PubMedCrossRef Kemmler G, Schmied B, Shetty-Lee A, Zangerle R, Hinterhuber H, Schüssler G, Mumelter B: Quality of life of HIV-infected patients: psychometric properties and validation of the German version of the MQOL-HIV. Qual Life Res 2003, 12: 1037–1050. 10.1023/A:1026114004548PubMedCrossRef
16.
go back to reference de Boer JB, van Dam FSAM, Sprangers MAG: Health-related quality-of-life evaluation in HIV-infected patients. A Review of the literature. Pharmacoeconomics 1995, 8: 291–304.PubMedCrossRef de Boer JB, van Dam FSAM, Sprangers MAG: Health-related quality-of-life evaluation in HIV-infected patients. A Review of the literature. Pharmacoeconomics 1995, 8: 291–304.PubMedCrossRef
17.
go back to reference Nieuwkerk PT, Gisolf EH, Reijers MHE, Lange JMA, Danner SA, Sprangers MAG: Long-term quality of life outcomes in three antiretroviral treatment strategies for HIV-1 infection. AIDS 2001, 15: 1985–1991. 10.1097/00002030-200110190-00011PubMedCrossRef Nieuwkerk PT, Gisolf EH, Reijers MHE, Lange JMA, Danner SA, Sprangers MAG: Long-term quality of life outcomes in three antiretroviral treatment strategies for HIV-1 infection. AIDS 2001, 15: 1985–1991. 10.1097/00002030-200110190-00011PubMedCrossRef
18.
go back to reference Burgoyne RW, Rourke SB, Behrens DM, Salit IE: Long-term quality-of-life outcomes among adults living with HIV in the HAART era: the interplay of changes in clinical factors and symptom profile. AIDS Behav 2004, 8: 151–163. 10.1023/B:AIBE.0000030246.19577.fbPubMedCrossRef Burgoyne RW, Rourke SB, Behrens DM, Salit IE: Long-term quality-of-life outcomes among adults living with HIV in the HAART era: the interplay of changes in clinical factors and symptom profile. AIDS Behav 2004, 8: 151–163. 10.1023/B:AIBE.0000030246.19577.fbPubMedCrossRef
19.
go back to reference Burgoyne R, Renwick R: Social support and quality of life over time among adults living with HIV in the HAART era. Soc Sci Med 2004, 58: 1353–1366. 10.1016/S0277-9536(03)00314-9PubMedCrossRef Burgoyne R, Renwick R: Social support and quality of life over time among adults living with HIV in the HAART era. Soc Sci Med 2004, 58: 1353–1366. 10.1016/S0277-9536(03)00314-9PubMedCrossRef
20.
go back to reference Brorsson B, Ifver J, Hays RD: The Swedish Health-Related Quality of Life Survey (SWED-QUAL). Qual Life Res 1993, 2: 33–45. 10.1007/BF00642887PubMedCrossRef Brorsson B, Ifver J, Hays RD: The Swedish Health-Related Quality of Life Survey (SWED-QUAL). Qual Life Res 1993, 2: 33–45. 10.1007/BF00642887PubMedCrossRef
21.
go back to reference Stewart AL, Hays RD, Ware JE: The MOS Short-form General Health Survey: Reliability and validity in a patient population. Med Care 1988, 26: 724–735.PubMedCrossRef Stewart AL, Hays RD, Ware JE: The MOS Short-form General Health Survey: Reliability and validity in a patient population. Med Care 1988, 26: 724–735.PubMedCrossRef
22.
go back to reference Tarlov AR, Ware JE, Greenfield S, Nelson EC, Perrin E, Zubkoff M: The Medical Outcomes Study. An application of methods for monitoring the results of medical care. JAMA 1989, 262: 925–930. 10.1001/jama.262.7.925PubMedCrossRef Tarlov AR, Ware JE, Greenfield S, Nelson EC, Perrin E, Zubkoff M: The Medical Outcomes Study. An application of methods for monitoring the results of medical care. JAMA 1989, 262: 925–930. 10.1001/jama.262.7.925PubMedCrossRef
23.
go back to reference Stewart AL, Sherbourne CD, Hays RD, Wells KB, Nelson EC, Kamberg CJ, Rogers WH, Berry SH, Ware JE: Summary and discussion of MOS measures. In Measuring Functioning and Well-Being The Medical Outcomes Study Approach. Edited by: Stewart AL, Ware JE. Duram, NC: Duke University Press; 1992:345–371. Stewart AL, Sherbourne CD, Hays RD, Wells KB, Nelson EC, Kamberg CJ, Rogers WH, Berry SH, Ware JE: Summary and discussion of MOS measures. In Measuring Functioning and Well-Being The Medical Outcomes Study Approach. Edited by: Stewart AL, Ware JE. Duram, NC: Duke University Press; 1992:345–371.
24.
go back to reference Ware JE, Sherbourne CD: The MOS 36-Item Short-Form Health Survey (SF-36). I. Conceptual framework and item selection. Med Care 1992, 30: 473–483.PubMedCrossRef Ware JE, Sherbourne CD: The MOS 36-Item Short-Form Health Survey (SF-36). I. Conceptual framework and item selection. Med Care 1992, 30: 473–483.PubMedCrossRef
25.
go back to reference Eriksson LE, Nordström G, Berglund T, Sandström E: The health-related quality of life in a Swedish sample of HIV-infected persons. J Adv Nurs 2000, 32: 1213–1223. 10.1046/j.1365-2648.2000.01592.xPubMedCrossRef Eriksson LE, Nordström G, Berglund T, Sandström E: The health-related quality of life in a Swedish sample of HIV-infected persons. J Adv Nurs 2000, 32: 1213–1223. 10.1046/j.1365-2648.2000.01592.xPubMedCrossRef
26.
go back to reference Morisky DE, Green LW, Levine DM: Concurrent and predictive validity of a self-reported measure of medication adherence. Med Care 1986, 24: 67–74.PubMedCrossRef Morisky DE, Green LW, Levine DM: Concurrent and predictive validity of a self-reported measure of medication adherence. Med Care 1986, 24: 67–74.PubMedCrossRef
27.
go back to reference 1994 revised guidelines for the performance of CD4+ T-cell determinations in persons with human immunodeficiency virus (HIV) infections. Centers for Disease Control and Prevention. MMWR Recom Rep 1994, 43: 1–21. 1994 revised guidelines for the performance of CD4+ T-cell determinations in persons with human immunodeficiency virus (HIV) infections. Centers for Disease Control and Prevention. MMWR Recom Rep 1994, 43: 1–21.
28.
go back to reference Hejdeman B, Lenkei R, Leandersson A-C, Hultström AL, Wahren B, Sandström E, Bratt G: Clinical and immunological benefits from highly active antiretroviral therapy in spite of limited viral load reduction in HIV type 1 infection. AIDS Res Hum Retroviruses 2001, 17: 277–286. 10.1089/08892220150503654PubMedCrossRef Hejdeman B, Lenkei R, Leandersson A-C, Hultström AL, Wahren B, Sandström E, Bratt G: Clinical and immunological benefits from highly active antiretroviral therapy in spite of limited viral load reduction in HIV type 1 infection. AIDS Res Hum Retroviruses 2001, 17: 277–286. 10.1089/08892220150503654PubMedCrossRef
29.
go back to reference Shott S: Statistics for health professionals. Philadelphia: W.B. Saunders Company; 1990. Shott S: Statistics for health professionals. Philadelphia: W.B. Saunders Company; 1990.
30.
go back to reference Fayers PM, Machin D: Quality of life: assessment, analysis, and interpretation. West Sussex, England: John Wiley & Sons Ltd; 2000.CrossRef Fayers PM, Machin D: Quality of life: assessment, analysis, and interpretation. West Sussex, England: John Wiley & Sons Ltd; 2000.CrossRef
31.
go back to reference Cohen J, Cohen P: Applied multiple regression/correlation analysis for the behavioral sciences. Second edition. Hillsdale, NJ: Lawrence Erlbaum Associates, Inc; 1983. Cohen J, Cohen P: Applied multiple regression/correlation analysis for the behavioral sciences. Second edition. Hillsdale, NJ: Lawrence Erlbaum Associates, Inc; 1983.
32.
go back to reference Wu AW, Rubin HR, Mathews WC, Brysk LM, Bozzette SA, Hardy WD, Atkinson JH, Grant I, Spector SA, McCutchan JA, Richman DD: Functional status and well-being in a placebo-controlled trial of zidovudine in early symptomatic HIV infection. J Acquir Immune Defic Syndr 1993, 6: 452–458.PubMedCrossRef Wu AW, Rubin HR, Mathews WC, Brysk LM, Bozzette SA, Hardy WD, Atkinson JH, Grant I, Spector SA, McCutchan JA, Richman DD: Functional status and well-being in a placebo-controlled trial of zidovudine in early symptomatic HIV infection. J Acquir Immune Defic Syndr 1993, 6: 452–458.PubMedCrossRef
33.
go back to reference Weinfurt KP, Willke RJ, Glick HA, Freimuth WW, Schulman KA: Relationship between CD4 count, viral burden, and quality of life over time in HIV-1-infected patients. Med Care 2000, 38: 404–410. 10.1097/00005650-200004000-00007PubMedCrossRef Weinfurt KP, Willke RJ, Glick HA, Freimuth WW, Schulman KA: Relationship between CD4 count, viral burden, and quality of life over time in HIV-1-infected patients. Med Care 2000, 38: 404–410. 10.1097/00005650-200004000-00007PubMedCrossRef
34.
go back to reference Goujard C, Bernard N, Sohier N, Peyramond D, Lançon F, Chwalow J, Arnould B, Delfraissy J-F: Impact of a patient education program on adherence to HIV medication. J Acquir Immune Defic Syndr 2003, 34: 191–194.PubMedCrossRef Goujard C, Bernard N, Sohier N, Peyramond D, Lançon F, Chwalow J, Arnould B, Delfraissy J-F: Impact of a patient education program on adherence to HIV medication. J Acquir Immune Defic Syndr 2003, 34: 191–194.PubMedCrossRef
35.
go back to reference Lubeck DP, Fries JF: Changes in quality of life among persons with HIV infection. Qual Life Res 1992, 1: 359–366. 10.1007/BF00704430PubMedCrossRef Lubeck DP, Fries JF: Changes in quality of life among persons with HIV infection. Qual Life Res 1992, 1: 359–366. 10.1007/BF00704430PubMedCrossRef
36.
go back to reference Low-Beer S, Chan K, Yip B, Wood W, Montaner JSG, O'Shaughnessy MV, Hogg RS: Depressive symptoms decline among persons on HIV protease inhibitors. J Acquir Immune Defic Syndr 2000, 23: 295–301.PubMedCrossRef Low-Beer S, Chan K, Yip B, Wood W, Montaner JSG, O'Shaughnessy MV, Hogg RS: Depressive symptoms decline among persons on HIV protease inhibitors. J Acquir Immune Defic Syndr 2000, 23: 295–301.PubMedCrossRef
37.
go back to reference Carrieri P, Spire B, Duran S, Katlama C, Peyramond D, Francois C, Chene G, Lang JM, Moatti JP, Leport C: Health-related quality of life after 1 year of highly active antiretroviral therapy. J Acquir Immune Defic Syndr 2003, 32: 38–47.PubMedCrossRef Carrieri P, Spire B, Duran S, Katlama C, Peyramond D, Francois C, Chene G, Lang JM, Moatti JP, Leport C: Health-related quality of life after 1 year of highly active antiretroviral therapy. J Acquir Immune Defic Syndr 2003, 32: 38–47.PubMedCrossRef
38.
go back to reference Rabkin J, Ferrando S, Lin S, Sewell M, McElhiney M: Psychological effect of HAART: a 2-year study. Psychosom Med 2000, 62: 413–422.PubMedCrossRef Rabkin J, Ferrando S, Lin S, Sewell M, McElhiney M: Psychological effect of HAART: a 2-year study. Psychosom Med 2000, 62: 413–422.PubMedCrossRef
39.
go back to reference Blanch J, Rousaud A, Martinez E, Lazzari ED, Milinkovic A, Peri J-M, Blanco J-L, Jaen J, Navarro V, Massana G, Gatell J-M: Factors associated with severe impact of lipodystrophy on the quality of life of patients infected with HIV-1. Clin Infect Dis 2004, 38: 1464–1470. 10.1086/383573PubMedCrossRef Blanch J, Rousaud A, Martinez E, Lazzari ED, Milinkovic A, Peri J-M, Blanco J-L, Jaen J, Navarro V, Massana G, Gatell J-M: Factors associated with severe impact of lipodystrophy on the quality of life of patients infected with HIV-1. Clin Infect Dis 2004, 38: 1464–1470. 10.1086/383573PubMedCrossRef
40.
go back to reference Hudson A, Kirksey K, Holzemer W: The influence of symptoms on quality of life among HIV-infected women. West J Nurs Res 2004, 26: 9–23. 10.1177/0193945903259221PubMedCrossRef Hudson A, Kirksey K, Holzemer W: The influence of symptoms on quality of life among HIV-infected women. West J Nurs Res 2004, 26: 9–23. 10.1177/0193945903259221PubMedCrossRef
41.
go back to reference Préau M, Leport C, Salmon-Ceron D, Carrieri P, Portier H, Chene G, Spire B, Choutet P, Raffi F, Morin M, APROCO Study Group: Health-related quality of life and patient-provider relationships in HIV-infected patients during the first three years after starting PI-containing antiretroviral treatment. AIDS Care 2004, 16: 649–661. 10.1080/09540120410001716441PubMedCrossRef Préau M, Leport C, Salmon-Ceron D, Carrieri P, Portier H, Chene G, Spire B, Choutet P, Raffi F, Morin M, APROCO Study Group: Health-related quality of life and patient-provider relationships in HIV-infected patients during the first three years after starting PI-containing antiretroviral treatment. AIDS Care 2004, 16: 649–661. 10.1080/09540120410001716441PubMedCrossRef
42.
go back to reference Tramarin A, Parise N, Campostrini S, Yin DD, Postma MJ, Lyu R, Grisetti R, Capetti A, Cattelan AM, Di Toro MT, Mastroianni A, Pignattari E, Mondardini V, Calleri G, Raise E, Starace F, Palladio Study Group: Association between diarrhea and quality of life in HIV-infected patients receiving highly active antiretroviral therapy. Qual Life Res 2004, 13: 243–250. 10.1023/B:QURE.0000015282.24774.36PubMedCrossRef Tramarin A, Parise N, Campostrini S, Yin DD, Postma MJ, Lyu R, Grisetti R, Capetti A, Cattelan AM, Di Toro MT, Mastroianni A, Pignattari E, Mondardini V, Calleri G, Raise E, Starace F, Palladio Study Group: Association between diarrhea and quality of life in HIV-infected patients receiving highly active antiretroviral therapy. Qual Life Res 2004, 13: 243–250. 10.1023/B:QURE.0000015282.24774.36PubMedCrossRef
43.
go back to reference Erlen JA, Mellors MP: Adherence to combination therapy in persons living with HIV: balancing the hardships and the blessings. J Assoc Nurses AIDS Care 1999, 10: 75–84.PubMedCrossRef Erlen JA, Mellors MP: Adherence to combination therapy in persons living with HIV: balancing the hardships and the blessings. J Assoc Nurses AIDS Care 1999, 10: 75–84.PubMedCrossRef
44.
go back to reference Holzemer WL, Corless IB, Nokes KM, Turner JG, Brown MA, Powell-Cope GM, Inouye J, Henry SB, Nicholas PK, Portillo CJ: Predictors of self-reported adherence in persons living with HIV disease. AIDS Patient Care STDS 1999, 13: 185–197.PubMedCrossRef Holzemer WL, Corless IB, Nokes KM, Turner JG, Brown MA, Powell-Cope GM, Inouye J, Henry SB, Nicholas PK, Portillo CJ: Predictors of self-reported adherence in persons living with HIV disease. AIDS Patient Care STDS 1999, 13: 185–197.PubMedCrossRef
45.
go back to reference Stone VE, Jordan J, Tolson J, Miller R, Pilon T: Perspectives on adherence and simplicity for HIV-infected patients on antiretroviral therapy (HAART) regimens in predicting adherence. J Acquir Immune Defic Syndr 2004, 36: 808–816.PubMedCrossRef Stone VE, Jordan J, Tolson J, Miller R, Pilon T: Perspectives on adherence and simplicity for HIV-infected patients on antiretroviral therapy (HAART) regimens in predicting adherence. J Acquir Immune Defic Syndr 2004, 36: 808–816.PubMedCrossRef
46.
go back to reference Fumaz CR, Tuldrà A, Ferrer MJ, Paredes R, Bonjoch A, Jou J, Negredo E, Romeu J, Sirera G, Tural C, Clotet B: Quality of life, emotional status, and adherence of HIV-1-infected patients treated with efavirenz versus protease inhibitor-containing regimens. J Acquir Immune Defic Syndr 2002, 29: 244–253.PubMedCrossRef Fumaz CR, Tuldrà A, Ferrer MJ, Paredes R, Bonjoch A, Jou J, Negredo E, Romeu J, Sirera G, Tural C, Clotet B: Quality of life, emotional status, and adherence of HIV-1-infected patients treated with efavirenz versus protease inhibitor-containing regimens. J Acquir Immune Defic Syndr 2002, 29: 244–253.PubMedCrossRef
Metadata
Title
The two-year impact of first generation protease inhibitor based antiretroviral therapy (PI-ART) on health-related quality of life
Authors
Lars E Eriksson
Göran A Bratt
Eric Sandström
Gun Nordström
Publication date
01-12-2005
Publisher
BioMed Central
Published in
Health and Quality of Life Outcomes / Issue 1/2005
Electronic ISSN: 1477-7525
DOI
https://doi.org/10.1186/1477-7525-3-32

Other articles of this Issue 1/2005

Health and Quality of Life Outcomes 1/2005 Go to the issue